As filed with the Securities and Exchange Commission on December 16, 2020
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM S‑8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
_____________________
Artelo Biosciences, Inc. |
(Exact name of Registrant as specified in its charter) |
_____________________
Nevada |
| 33-1220924 |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification Number) |
888 Prospect Street, Suite 210
La Jolla, CA 92037
(760) 943-1689
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
_____________________
Artelo Biosciences, Inc. 2018 Equity Incentive Plan |
(Full title of the plan) |
Gregory D. Gorgas
Chief Executive Officer and President
888 Prospect Street, Suite 210
La Jolla, CA 92037
Telephone: (760) 943-1689
(Name, address, including zip code, and telephone number, including area code, of agent for service)
_____________________
Copies to:
Martin J. Waters
Wilson Sonsini Goodrich & Rosati, P.C.
12235 El Camino Real
San Diego, CA 92130
Telephone: (858) 350-2300
Facsimile: (858) 350-2399
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. o
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered |
| Amount to be Registered(1) |
|
| Proposed Maximum Offering Price Per Share(2) |
|
| Proposed Maximum Aggregate Offering Price |
|
| Amount of Registration Fee |
| ||||
Common Stock, $0.001 par value per share, reserved for issuance pursuant to the Artelo Biosciences, Inc. 2018 Equity Incentive Plan, as amended |
|
| 2,748,738 | (2) |
| $ | 0.635 |
|
| $ | 1,745,448.63 |
|
| $ | 190.43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Registration Fee |
|
|
|
|
|
|
|
|
| $ | 1,745,448.63 |
|
| $ | 190.43 |
|
___________
(1) | Pursuant to Rule 416(a) of the Securities Act of 1933 (the “Securities Act”), as amended, this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Artelo Biosciences, Inc. 2018 Equity Incentive Plan, as amended (“2018 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock. |
(2) | Estimated solely for purposes of calculating the registration fee on the basis of $0.635 per share, in accordance with Rule 457(c) and (h) of the Securities Act, based upon the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Stock market LLC on December 4, 2020. |
2 |
PART I
INFORMATION REQUIRED IN THE PROSPECTUS
This Registration Statement on Form S-8 (the “Registration Statement”) registers 2,748,738 additional shares of the common stock of Artelo Biosciences, Inc. (the “Registrant”) that may be issued pursuant to the Registrant’s Amended and Restated 2018 Equity Incentive Plan, as amended and restated (the “2018 Plan”).
In accordance with General Instruction E to Form S-8, the contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on January 15, 2020 (File No. 333-235916) and June 25, 2020 (File No. 333-239434) (the “Previous Form S-8s”) are incorporated by reference into this Registration Statement.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Artelo Biosciences, Inc. (the “Registrant” or “Artelo”) hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):
| • | Artelo’s Annual Report on Form 10-K for the fiscal year ended August 31, 2020 filed on November 4, 2020; |
| • | Artelo’s Current Reports on Form 8-K filed on October 14, 2020, November 20, 2020, December 2, 2020, and December 4, 2020; and |
| • | Artelo’s description of its common stock set forth in the registration statement on Form 8-A registering the common stock under Section 12 of the Exchange Act filed on June 21, 2019, including any amendments or reports filed for purposes of updating such description. |
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
Exhibit Number | Description | |
Consent of MaloneBailey, LLP, Independent Registered Public Accounting Firm. | ||
Consent of Fennemore Craig, P.C. (contained in Exhibit 5.1 hereto). | ||
|
+ | Indicates management contract or compensatory plan, contract or arrangement. |
3 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on December 16, 2020.
| ARTELO BIOSCIENCES, INC. | ||
| By: | /s/ Gregory D. Gorgas | |
| Name: | Gregory D. Gorgas | |
| Title: | President & Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Gregory D. Gorgas, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments), to this Registration Statement on Form S-8 with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:
Name |
| Title |
| Date |
| ||||
/s/ Gregory D. Gorgas |
| President, Chief Executive Officer and Director |
| December 16, 2020 |
Gregory D. Gorgas |
| (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) | ||
| ||||
/s/ Connie Matsui |
| Director, Chair of the Board |
| December 16, 2020 |
Connie Matsui | ||||
| ||||
/s/ Steven Kelly |
| Director |
| December 16, 2020 |
Steven Kelly | ||||
| ||||
/s/ Douglas Blayney |
| Director |
| December 16, 2020 |
Douglas Blayney | ||||
| ||||
/s/ R. Martin Emanuele |
| Director |
| December 16, 2020 |
R. Martin Emanuele | ||||
| ||||
/s/ John W. Beck |
| Director |
| December 16, 2020 |
John W. Beck | ||||
|
|
|
|
|
/s/ Gregory R. Reyes |
| Director |
| December 16, 2020 |
Gregory R. Reyes |
|
|
|
|
4 |